Here, we postulate that the promotion of squamous cell differentiation by EGFR inhibitors may suppress the growth of ESCC cells, which would contribute to establishing “differentiation therapy” for ESCC. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.